Granulocyte colony-stimulating factors are widely used to reduce myelotoxicity of chemotherapy and to allow its regular administration. National and international guidelines regulate their use. The aim of the study was to evaluate the use of pegfilgrastim and filgrastim/lenograstim in clinical practice, adherence to ASCO and ESMO guidelines, chemotherapy-related complications and adverse reactions.
Granulocyte colony-stimulating factors used in clinical practice : PoloNord registry-based cohort Italian study / D. Fagnani, L. Isa, M.F. Verga, P. Nova, C. Casartelli, V. Filipazzi, M. Danova, G. Farina, P. Pugliese, S. Fava, A. Bertolini, C. Cimminiello, P. Boracchi, G. Marano, C. Panzarino, POLONORD Group. - In: TUMORI. - ISSN 2038-2529. - 100:5(2014), pp. 491-498.
Titolo: | Granulocyte colony-stimulating factors used in clinical practice : PoloNord registry-based cohort Italian study | |
Autori: | MARANO, GIUSEPPE (Penultimo) | |
Parole Chiave: | cancer; chemotherapy-induced neutropenia; febrile neutropenia; granulocyte colony-stimulating factors | |
Settore Scientifico Disciplinare: | Settore MED/01 - Statistica Medica Settore MED/06 - Oncologia Medica | |
Data di pubblicazione: | 2014 | |
Rivista: | ||
Tipologia: | Article (author) | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1700/1660.18158 | |
Appare nelle tipologie: | 01 - Articolo su periodico |